Answers are grounded in this paper and cite their sources.
Shows increased bacterial load in type 2 diabetes subphenotypes, indicating risk for complications.
Introduction and Objective: Clinical sub-phenotypes of type 2 diabetes (T2D) have been identified and highly differ in their risk for complications. Yet, the reasons for this pleiotropic clinical presentation remain largely unknown. One of the factors associated with obesity, insulin resistance and T2D is the human gut microbiota. However, most studies rely on stool samples to study the gut microbiota, whereas the main site for nutrient absorption and incretin production is the small intestine which is scarcely explored. Here, we close this knowledge gap and investigate the human small intestinal microbiota an its association with T2D sub-phenotypes. Methods: We collected jejunal content fluids from 627 individuals undergoing bariatric surgery with metabolic phenotyping. Microbial DNA was extracted using an optimized protocol for low-abundance biomasses to recover three dominant microbial kingdoms: bacteria, fungi, and archaea. Microbe quantification was performed by digital PCR, with an accuracy of one gene copy. Results: Absolute quantification of microbial DNA revealed a bacterial range of < 2 to 56 x 106 Genome Copies (GC)/mL (median= 1023, [IQR= 3641]), 0 to 6343 GC/mL (median= 1, [4]) for fungi and 0 to 2387 GC/mL for archaea (median= 0, [0]). We found that Individuals with T2D had a significant higher bacterial load compared to those without T2D (median= 1410, [IQR= 9228] vs 902, [2416], p=0.0014). In association with the clinical sub-phenotypes, high-risk diabetes cluster (severe insulin resistant diabetes) had significantly higher bacterial DNA abundance vs the mild obesity-related cluster (median = 9908, [IQR=121163] vs 13623 [5578], p= 0.039). We did not observe associations of the clinical T2D clusters with archaea and fungi abundance. Conclusion: These are the first large-scale human jejunal microbiome data, showing increased bacterial colonization of the small intestine in individuals with T2D and specifically from a high-risk sub-phenotype. Disclosure A. Makour: None. S. Gschwendtner: None. M. Schloter: None. A.L. Birkenfeld: None. B. Diel: None. F. Pattou: Advisory Panel; Current; Lilly. Consultant; Current; Novo Nordisk. Advisory Panel; Current; Boehringer Ingelheim International GmbH. Consultant; Ended; Medtronic. Consultant; Current; Ethicon, Inc., ADOCIA. R.J. von Schwartzenberg: None.
No takes yet. Share an insight, caveat, or question.
Makour et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: